Pfizer Clinches Deal For Obesity Drug Developer Metsea After A Bidding War With Novo Nordisk - Beritaja

NEW YORK (AP) — U.S. pharmaceutical elephantine Pfizer signed a woody to acquisition development-stage obesity drugmaker Metsera Inc., winning a bidding warfare against Novo Nordisk, the Danish drugmaker down weight-loss treatments Ozempic and Wegovy.

Metsera, based successful New York, has nary products connected the market, but it is processing oral and injectable treatments. That includes immoderate imaginable treatments that could target lucrative fields for obesity and diabetes.

The woody comes arsenic Phizer is attempting to create its ain liking successful that market, respective months aft ending improvement of a imaginable pill curen for obesity.

In a connection issued Friday, Metsera said Pfizer will get the institution for up to $86.25 per share, consisting of $65.60 per stock successful rate and a contingent worth correct entitling holders to further payments of up to $20.65 per stock successful cash.

Metsera cited U.S. antitrust risks successful Novo’s bid, saying successful its connection that the committee has wished Pfizer’s revised position correspond “the champion transaction for shareholders, some from the position of worth and certainty of closing.”

The woody comes 3 days aft Novo Nordisk raised the stakes successful its push to outbid Pfizer, saying Tuesday it would connection to salary arsenic overmuch arsenic $10 cardinal for Metsera. That was higher than its erstwhile bid of up to $9 cardinal which sparked a suit from Pfizer.

Pfizer had besides altered the connection it made successful September of about $4.9 cardinal to supply much rate up front, Metsera had said.

New York-based Pfizer said successful an email that it was happy pinch the position of the deal, and expects to adjacent the transaction soon pursuing the Metsera shareholder gathering connected Nov. 13.

Novo Nordisk said Saturday it would not summation its connection and would time off the title to get Metsera.

Novo’s projected woody had progressive paying $62.20 successful rate for each Metsera share, up from its erstwhile bid of $56.50. The Danish drugmaker planned to tack connected a contingent worth correct costs of $24, different betterment from its erstwhile bid, if definite improvement and regulatory milestones were met.

---

you are at the end of the news article with the title:

"Pfizer Clinches Deal For Obesity Drug Developer Metsea After A Bidding War With Novo Nordisk - Beritaja"

---

Please read other interesting content from Beritaja.com at Google News and Whatsapp Channel!